Pharma KOLs to Unite at Access Insights Conference 2024
This year’s conference—taking place in Washington, DC— will prioritize the tackling of business, economic, and healthcare policy obstacles when it comes to decision marking and net revenue optimization.
IntegriChain, a data and business process platform for the pharmaceutical industry, has revealed the lineup of pharma industry subject matter experts that are slated to speak at its annual Access Insights Conference, co-hosted with Blue Fin Group and Federal Compliance Solutions.1 The event will be held Oct. 14-16, 2024, at The Mayflower Hotel, Autograph Collection, in Washington, DC—as we were last year, Pharma Commerce is one of the conference sponsors.
Speakers consist of experts in the healthcare policy, pharmacy, and pharmaceutical business leadership spaces, while also including financial and industry analysts.
Some of the key opinion leaders (KOLs) include:
- Meenakshi Datta, Partner, Sidley Austin
- B. Douglas Hoey, CEO, National Community Pharmacists Association
- Pat Lupo, Group Vice President, Pharmacy Trade and Specialty, Walgreens
- Chris Mancill, Senior Vice President & Head, Market Access, Pricing, and Value Demonstration (MAx), Bristol Meyers Squibb
- Jim Meyers, Chairman of the Board, IntegriChain
- John Robiscek, Assistant Vice President – Strategy, Business, and Program Development, Atrium Health
- Sarit Roy, Founder & CEO, OnPoint Pharmacy
- William Sarraille, Professor, University of Maryland Francis King Carey School of Law
- Lisa Smith, PharmD, Group Director, Pharmacy Clinical Operations and Strategy, Walmart
- Albert Thigpen, Co-Founder, Talentwise Consulting
- Alice Valder Curran, Partner, Hogan Lovells
- Lance Wilkes, VP, Senior Equity Analyst, Sanford C. Bernstein
“The Pharma industry faces immense headwinds from new healthcare policy initiatives, crushing pricing pressures, challenging patient journeys, and the drum-beating drive from investors for net revenue optimization,” said Josh Halpern, CEO of IntegriChain. “We designed our agenda and hand-picked some of the industry’s greatest thinkers who will speak their mind and share their insights about how the industry can continue to bring exciting science to market and optimize their financial performance. We are immensely grateful to all of our guest speakers and we look forward to this ‘can’t miss’ industry event.”
Pharma Commerce will be onsite covering sessions and conducting KOL video interviews.2 One of the concepts that Bill Roth—SVP of IntegriChain’s consulting business and Pharma Commerce editorial advisory board—discussed with us last year were the steps that could be taken by chief commercial offers in planning for a profitable lifecycle.
“The first thing you have to do is think about three things: What product archetype am I working in? What therapeutic area am I in? What drug class am I in? From there, you really ask if your therapy is novel in an unmet need area or is it a commodity. So, if you're launching a cell and gene therapy, oncology, or even in a multiple sclerosis area, it's all very different. Launching in GenMed right now is a tough one. You're looking at 60% rebates to the PBM and double digit figures to the wholesaler for distribution. By the time you stack everything on, it's hard to make money.
“The hard part for chief commercial officers is how different the game is now. It's even more different than it was five years ago. Things we used to view in absolutes are not the case anymore. It's not showing up yet in the data, but it is diversified.”
References
1. Access Insights Conference. https://web.cvent.com/event/83a659ca-a920-4660-bf04-175437dbab59/summary
2. Pharma Commerce Access Insights Conference coverage. https://www.pharmaceuticalcommerce.com/conferences/access-insights-conference
